CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (24,144)	$ (29,204)
Adjustment to reconcile net loss to net cash used in operating activities:
Non-cash stock-based compensation	1,191	1,597
Non-cash lease expense	413	367
Change in fair value of common stock warrants	0	(4)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(2,130)	(581)
Accounts payable	(1,021)	983
Accrued expenses and other current liabilities	(2,160)	643
Operating lease liabilities	(398)	(386)
Net cash used in operating activities	(28,249)	(26,585)
Cash flows from investing activities:
Cash paid for acquisition of in-process research and development	0	(5,500)
Net cash used in investing activities	0	(5,500)
Cash flows from financing activities:
Proceeds from issuance of common stock and common stock warrants, net of issuance costs	46,093	18,554
Proceeds from issuance of common stock, net of issuance costs	0	268
Proceeds from the exercise of common stock warrants	559	0
Proceeds from employee stock purchases	98	107
Net cash provided by financing activities	46,750	18,929
Net increase (decrease) in cash, cash equivalents, restricted cash, and restricted cash equivalents	18,501	(13,156)
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period	2,630	17,225
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period	21,131	4,069
Supplemental disclosure of cash flow information:
Cash received during the period for interest	451	484
Supplemental disclosure of non-cash investing and financing activities:
Offering expenses included in accounts payable and accrued expenses and other current liabilities	71	0
Warrant modifications recorded in stockholders' equity (deficit)	$ 725	$ 0